Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
August 03 2021 - 4:05PM
Business Wire
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology
company with a mission to discover, develop and deliver curative
therapies that address the underlying causes of heart disease,
announced today the closing of its underwritten, upsized initial
public offering of 13,800,000 shares of its common stock, which
includes the exercise in full of the underwriters’ option to
purchase 1,800,000 additional shares of its common stock, at an
initial public offering price of $15.00 per share. The aggregate
gross proceeds from the offering were $207.0 million, before
deducting underwriting discounts and commissions and offering
expenses payable by Tenaya. All shares in the offering were offered
by Tenaya. The shares began trading on the Nasdaq Global Select
Market on July 30, 2021, under the ticker symbol “TNYA.”
Morgan Stanley, Cowen and Piper Sandler acted as joint
book-running managers for the offering. Chardan acted as lead
manager for the offering.
Registration statements relating to the offering have been filed
with the Securities and Exchange Commission and became effective on
July 29, 2021. The offering is made only by means of a prospectus.
Copies of the final prospectus may be obtained from: Morgan Stanley
& Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014; Cowen and Company, LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717,
Attn: Prospectus Department, by telephone at (833) 297-2926, or by
email at PostSaleManualRequests@broadridge.com; or Piper Sandler
& Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn:
Prospectus Department, by telephone at (800) 747-3924, or by email
at prospectus@psc.com. Copies of the registration statements
related to the offering are available at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor will there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful before
registration or qualification under the securities laws of that
state or jurisdiction.
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a
bold mission: to discover, develop and deliver curative therapies
that address the underlying drivers of heart disease. Founded by
leading cardiovascular scientists from Gladstone Institutes and the
University of Texas Southwestern Medical Center, Tenaya is
developing therapies for rare genetic disorders as well as for more
prevalent heart conditions through three distinct but interrelated
product platforms: Gene Therapy, Cellular Regeneration and
Precision Medicine.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803006033/en/
Media Contact: Wendy Ryan Ten Bridge Communications
wendy@tenbridgecommunications.com (781) 316-4424
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Aug 2023 to Aug 2024